There has been great progress in recent decades in the treatment of pediatric cancers, with high cure rates possible today for several childhood malignancies. Prognosis remains poor, however, for children diagnosed with a number of pediatric cancers, and many existing therapies are associated with long-term side effects that impact survivors' life expectancy and/or quality of life. Writing in the journal Science Translational Medicine, an international team of scientists from the Children's Cancer Institute-Australia (CCIA), Roswell Park Cancer Institute (RPCI) and Incuron LLC report significant progress toward addressing these persistent challenges.
The CCIA's Daniel Carter, PhD, Glenn Marshall, MD, and co-authors report that they have identified a new treatment approach for a highly aggressive and usually fatal subtype of neuroblastoma, a cancer of nerve cells that is one of the most frequent solid tumors in children. The researchers provide evidence that the protein complex FACT (facilitates chromatin transcription) represents a new and promising biomarker candidate and a target for treatment of this aggressive, treatment-resistant disease. They observe that a FACT-targeting drug candidate -- CBL0137, which was developed by the biotech company Incuron in collaboration with scientists from RPCI -- has demonstrated significant antitumor activity in preclinical models of neuroblastoma.
CBL0137 is a small molecule that belongs to a class of agents called curaxins, which were invented by a group that included paper co-author Andrei Gudkov, PhD, DSci, Senior Vice President for Basic Science at Roswell Park and founder and Chief Scientific Officer of Incuron.
"This work, which beautifully demonstrates the power of international collaboration of oncology researchers working both at academic centers and private enterprises, gives us hope that we will see improved cure rates and long-term outcomes for children afflicted with this aggressive disease," says Dr. Gudkov. "We hope to soon be able to extend the opportunity to participate in clinical studies of curaxin CBL0137 to children with neuroblastoma, a prospect we eagerly await given the limited treatment options available currently."
While another target for this subtype of neuroblastoma, the MYC oncogene, exists, efforts to effectively reach this target by pharmacological agents have so far proven unsuccessful. The study in Science Translational Medicine for the first time demonstrates that MYC activity in these tumors depends on the presence of FACT and that inactivation of FACT effectively neutralizes MYC, resulting in the death of neuroblastoma cells.
"Remarkably, the presence of FACT in this type of tumor appeared to be as bad a prognostic marker as excessive activity of MYC is," notes paper co-author Katerina Gurova, MD, PhD, of the Roswell Park Department of Cell Stress Biology, who led efforts to decipher the mechanisms of activity through which curaxins successfully target FACT, as documented in earlier published research.
CBL0137, which is being developed by Incuron, is currently being assessed in a phase I clinical trial in adults with advanced metastatic solid-tumor cancers and lymphomas at RPCI and several other U.S. cancer centers (study NCT01905228). As distinct from many of the drugs currently used to treat neuroblastoma, curaxins appear to kill cancer cells without causing DNA damage, the major source of cancer treatment side effects.
This work was funded in part by grants from Incuron LLC to some authors. The researchers also credit early funding from the Roswell Park Alliance Foundation as critical to these latest efforts.
Cite This Page: